Lin Chia-Yang, Islam Atikul, Su Claire J, Tikhomirov Alexander S, Shchekotikhin Andrey E, Chuang Show-Mei, Chueh Pin Ju, Chen Yao Li
Institute of Biomedical Sciences, National Chung Hsing University, Taichung 40227, Taiwan.
Morrison Academy in Taichung, 216 Si Ping Road, Taichung 40679, Taiwan.
Cancers (Basel). 2019 Mar 24;11(3):420. doi: 10.3390/cancers11030420.
Hepatocellular carcinoma (HCC) is the most frequent primary malignancy of the liver and is among the top three causes of cancer-associated death worldwide. However, the clinical use of chemotherapy for HCC has been limited by various challenges, emphasizing the urgent need for novel agents with improved anticancer properties. We recently synthesized and characterized a series of 4,11-diaminoanthra[2,3-]furan-5,10-dione derivatives that exhibit potent apoptotic activity against an array of cancer cell lines, including variants with multidrug resistance. Their effect on liver cancer cells, however, was unknown. Here, we investigated three selected 4,11-diaminoanthra[2,3-]furan-5,10-dione derivatives (compounds ⁻) for their cytotoxicity and the underlying molecular mechanisms in wild-type or p53-deficient HCC cells. Cytotoxicity was determined by WST-1 assays and cell impedance measurements and apoptosis was analyzed by flow cytometry. The interaction between compounds and tumor-associated NADH oxidase (tNOX, ENOX2) was studied by cellular thermal shift assay (CETSA). We found that compound and induced significant cytotoxicity in both HepG2 and Hep3B lines. CETSA revealed that compounds and directly engaged with tNOX, leading to a decrease in the cellular NAD⁺/NADH ratio. This decreased the NAD⁺-dependent activity of Sirtuin 1 (SIRT1) deacetylase. In p53-wild-type HepG2 cells, p53 acetylation/activation was enhanced, possibly due to the reduction in SIRT1 activity, and apoptosis was observed. In p53-deficient Hep3B cells, the reduction in SIRT1 activity increased the acetylation of c-Myc, thereby reactivating the TRAIL pathway and, ultimately leading to apoptosis. These compounds thus trigger apoptosis in both cell types, but via different pathways. Taken together, our data show that derivatives and of 4,11-diaminoanthra[2,3-]furan-5,10-diones engage with tNOX and inhibit its oxidase activity. This results in cytotoxicity via apoptosis through tNOX-SIRT1 axis to enhance the acetylation of p53 or c-Myc in HCC cells, depending on their p53 status.
肝细胞癌(HCC)是最常见的原发性肝脏恶性肿瘤,也是全球癌症相关死亡的三大主要原因之一。然而,HCC化疗的临床应用受到各种挑战的限制,这凸显了对具有更好抗癌特性的新型药物的迫切需求。我们最近合成并表征了一系列4,11 - 二氨基蒽[2,3 - ]呋喃 - 5,10 - 二酮衍生物,这些衍生物对一系列癌细胞系表现出强大的凋亡活性,包括具有多药耐药性的变体。然而,它们对肝癌细胞的作用尚不清楚。在此,我们研究了三种选定的4,11 - 二氨基蒽[2,3 - ]呋喃 - 5,10 - 二酮衍生物(化合物⁻)在野生型或p53缺陷型HCC细胞中的细胞毒性及其潜在分子机制。通过WST - 1测定法和细胞阻抗测量来确定细胞毒性,并通过流式细胞术分析细胞凋亡。通过细胞热位移分析(CETSA)研究化合物与肿瘤相关的NADH氧化酶(tNOX,ENOX2)之间的相互作用。我们发现化合物 和 在HepG2和Hep3B细胞系中均诱导了显著的细胞毒性。CETSA显示化合物 和 直接与tNOX结合,导致细胞内NAD⁺/NADH比值降低。这降低了沉默调节蛋白1(SIRT1)脱乙酰酶的NAD⁺依赖性活性。在p53野生型HepG2细胞中,p53乙酰化/激活增强,这可能是由于SIRT1活性降低所致,并观察到细胞凋亡。在p53缺陷型Hep3B细胞中,SIRT1活性降低增加了c - Myc的乙酰化,从而重新激活TRAIL途径,并最终导致细胞凋亡。因此,这些化合物通过不同途径在两种细胞类型中均触发细胞凋亡。综上所述,我们的数据表明4,11 - 二氨基蒽[2,3 - ]呋喃 - 5,10 - 二酮的衍生物 和 与tNOX结合并抑制其氧化酶活性。这通过tNOX - SIRT1轴导致细胞毒性,通过凋亡增强HCC细胞中p53或c - Myc的乙酰化,这取决于它们的p53状态。